UBS Group
ANTH

UBS Group’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

UBS Group’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-113,817
Closed -$36K – 8512
2018
Q1 		$36K Buy
113,817
+48,941
+75% +$73.1K ﹤0.01% 5967
2017
Q4 		$107K Sell
64,876
-16,306
-20% -$28.1K ﹤0.01% 5308
2017
Q3 		$117K Buy
81,182
+22,730
+39% +$32.3K ﹤0.01% 5226
2017
Q2 		$95K Buy
58,452
+11,453
+24% +$25.7K ﹤0.01% 5209
2017
Q1 		$160K Buy
46,999
+4,238
+10% +$20K ﹤0.01% 4784
2016
Q4 		$222K Buy
42,761
+16,531
+63% +$286K ﹤0.01% 4724
2016
Q3 		$661K Buy
26,230
+14,266
+119% +$360K ﹤0.01% 3720
2016
Q2 		$296K Buy
11,964
+2,339
+24% +$66.1K ﹤0.01% 4274
2016
Q1 		$279K Buy
9,625
+5,062
+111% +$137K ﹤0.01% 4242
2015
Q4 		$169K Buy
4,563
+2,184
+92% +$96.4K ﹤0.01% 4797
2015
Q3 		$116K Buy
2,379
+1,705
+253% +$119K ﹤0.01% 5105
2015
Q2 		$47K Buy
674
+549
+439% +$25.4K ﹤0.01% 6060
2015
Q1 		$4K Sell
125
-250
-67% -$7.4K ﹤0.01% 8262
2014
Q4 		$5K Buy
+375
New +$5.45K ﹤0.01% 9037

Other funds holding ANTH

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS Group's ANTH Position: Q2 2018 in Review

UBS Group sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 113,817 shares — an estimated $36K sold.

UBS Group first reported a position in ANTH in Q4 2014 and held it in 14 quarters. The position peaked at $661K in Q3 2016. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

  • UBS Group reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • UBS Group sold 113,817 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $36K.
  • UBS Group first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2014 and held it in 14 quarters.
  • UBS Group's Anthera Pharmaceuticals, Inc. position peaked at $661K in Q3 2016.
  • 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.